ANGPTL3 and homozygous familial hypercholesterolemia: In 2020, the Evinacumab Lipid Studies in Patients with Homozygous Familial Hypercholesterolemia (ELIPSE HoFH) trial evaluated the efficacy of evinacumab, a monoclonal antibody against ANGPTL3, in reducing LDL-C in patients with a genetic or clinical diagnosis of HoFH [138].